Observational studyBMC cancer2021

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.

Ana Elena Martín-Aguilar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.